Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers

[20] Processing of X-ray diffraction data collected in oscillation mode

Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · see citing works

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works

<i>Phaser</i> crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Towards automated crystallographic structure refinement with <i>phenix.refine</i>

Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · see citing works

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · see citing works

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · see citing works

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · see citing works

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730 · see citing works

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · see citing works

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · see citing works

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A. M., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 424 · see citing works

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Tsou, H., Overbeek, E., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C. M., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 302 · see citing works

Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis

Ryckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 282 · see citing works

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279 · see citing works

Optimized Fast and Sensitive Acquisition Methods for Shotgun Proteomics on a Quadrupole Orbitrap Mass Spectrometer

Kelstrup, C. D., Young, C., Lavallee, R. J., Nielsen, M. L., & Olsen, J. V. (2012) · Journal of Proteome Research · doi:10.1021/pr3000249 · Cited by 279 · see citing works

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N. N., Rosfjord, E. C., Discafani, C. M., Davis, R. E., Shi, X., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 270 · see citing works

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269 · see citing works

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226 · see citing works

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Kim, Y.-W., Ko, J., Cui, Z.-Y., Abolhoda, A., Ahn, J. S., Ou, S.-H., Ahn, M., & Park, K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0750 · Cited by 179 · see citing works

Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper

Wang, Z., Liu, J., Sudom, A. M., et al. (2006) · Structure · doi:10.1016/j.str.2006.11.001 · Cited by 145 · see citing works

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121 · see citing works

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4

Powers, J. P., Li, S., Jaén, J. C., Liu, J., Walker, N. P. C., Wang, Z., & Wesche, H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.020 · Cited by 118 · see citing works

Afatinib—new therapy option for EGFR-mutant lung cancer

Yu, H. A., & Pao, W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.154 · Cited by 105 · see citing works

Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review

Köhler, J., & Schüler, M. (2013) · Oncology Research and Treatment · doi:10.1159/000354627 · Cited by 91 · see citing works

Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant

Chang, S., Zhang, L., Xu, S., Luo, J., Lu, X., Zhang, Z., Xu, T., Liu, Y., Tu, Z., Xu, Y., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201591k · Cited by 85 · see citing works

In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Sjin, R. T. T., Lee, K., Walter, A. O., Dubrovskiy, A., Sheets, M. P., Martin, T. S., Labenski, M., Zhu, Z., Tester, R. W., Karp, R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0966 · Cited by 68 · see citing works

Discovery of selective irreversible inhibitors for EGFR-T790M

Zhou, W., Ercan, D., Janne, P. A., & Gray, N. S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.036 · Cited by 67 · see citing works

Hit-to-lead studies on benzimidazole inhibitors of ITK: Discovery of a novel class of kinase inhibitors

Snow, R. J., Abeywardane, A., Campbell, S. J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.045 · Cited by 66 · see citing works

Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants

Xu, T., Zhang, L., Xu, S., Yang, C., Luo, J., Ding, F., Lu, X., Liu, Y., Tu, Z., Li, S., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302313 · Cited by 37 · see citing works

Evaluating the utility of the HTRF® Transcreener™ ADP assay technology: A comparison with the standard HTRF assay technology

Hong, L., Quinn, C. M., & Jia, Y. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.04.033 · Cited by 30 · see citing works

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Tan, D. S.-W., Seto, T., Leighl, N. B., Riely, G. J., Sequist, L. V. D., Felip, E., Wolf, J., Yang, J. C., Matushansky, I., Yu, X., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8013 · Cited by 28 · see citing works

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Singh, J., Evans, E. K., Hagel, M., Labinski, M., Dubrovskiy, A., Nacht, M., Petter, R. C., Prasad, A., Sheets, M. P., Martin, T. S., et al. (2012) · MedChemComm · doi:10.1039/c2md20017a · Cited by 27 · see citing works

Interstrain Differences of In Vitro Metabolic Stability and Impact on Early Drug Discovery

Richmond, W., Wogan, M., Isbell, J. J., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22179 · Cited by 23 · see citing works

Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant

Xu, S., Zhang, L., Chang, S., Luo, J., Lu, X., Tu, Z., Liu, Y., Zhang, Z., Xu, Y., Ren, X., et al. (2012) · MedChemComm · doi:10.1039/c2md20078c · Cited by 18 · see citing works

Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4

Wang, Z., Sun, D., Johnstone, S., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.060 · Cited by 12 · see citing works

HTRF Kinase Assay Development and Methods in Inhibitor Characterization

Jia, Y., Manuia, M., & Juarez, J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3073-9_1 · Cited by 12 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

Nagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219 · see citing works

Targeting EGFR ^L858R/T790M and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry

Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173 · see citing works

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121 · see citing works

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97 · see citing works

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC

Zeng, H., Castillo-Cabrera, J., Manser, M., Lu, B., Yang, Z., Strande, V., Begue, D., Zamponi, R., Qiu, S., Sigoillot, F., et al. (2019) · eLife · doi:10.7554/elife.50223 · Cited by 57 · see citing works

21 High sensitivity detection of epidermal growth factor receptor (EGFR) T790M mutants in non-small-cell lung cancer

Tracey, J., Clark, C., Bell, C., et al. (2013) · Lung Cancer · doi:10.1016/s0169-5002(13)70021-7

9017 POSTER DISCUSSION Initial Detection of the Double Epidermal Growth Factor Receptor (EGFR) Mutation (L858R or Deletion in Exon 19 [del 19] Plus T790M) in Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Brain Metastases (mets) and the Influence of First-Line Chemotherapy on Outcome to Erlotinib

Rolfo, C. D., Morán, T., Sánchez, J. M., et al. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)72329-2

Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy

Aggarwal, S., Patil, S., & Rohtagi, N. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_510_17 · Cited by 8 · see citing works

Response to First-Line Osimertinib Treatment in Non–Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations

Ikari, T., Sakakibara‐Konishi, J., Yamamoto, G., Kitai, H., Mizugaki, H., Asahina, H., Kikuchi, E., & Shinagawa, N. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.002 · Cited by 2 · see citing works

Detection of epidermal growth factor receptor-T790M mutation in circulating tumor DNA of lung cancer patients for tyrosine kinase inhibitor acquired resistance

Yang, X. (2018) · Chinese Journal of Asthma · doi:10.3760/cma.j.issn.1673-436x.2018.04.011